GLIORESOLVE Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment
- Coordinator
- Royal College of Surgeons in Ireland, Ireland
- Runs
- 1 September 2022 to 31 August 2026
- Status
- Running
- EU funding
- €2.7m
- Total cost
- —
- Partners
- 24 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101073386
What the project is doing
In the project's own words, from its summary on CORDIS.
Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address European applied biomedical research training needs and will train 10 innovative, entrepreneurial doctoral researchers (DRs).
The research objectives of GLIORESOLVE are i) to extend immunotherapy options to IDHwt GBM patients and identify novel tumour microenvironment (TME) subtype-specific therapeutic targets, (ii) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (iii) test novel rationally selected (available) drugs / drug combinations for precision treatment of IDHwt GBM based on TME subtype assignment.
Cumulatively, the programme seeks to generate sufficient data to support a post-project Phase 2 clinical trial. The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology. Overall GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease.
The GLIORESOLVE network addresses current needs in academia and the private sector to train doctoral researchers in an environment that spans multiple disciplines. Thus, GLIORESOLVE DRs will be able to navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Royal College of Surgeons in Ireland | Dublin 2 | Ireland | Coordinator |
| Katholieke Universiteit Leuven | Leuven | Belgium | Participant |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Participant |
| Mount Sinai Hospital | Toronto | Canada | Associatedpartner |
| Bayer Aktiengesellschaft | Leverkusen | Germany | Participant |
| Charite - Universitaetsmedizin Berlin | Berlin | Germany | Associatedpartner |
| Genexplain GmbH | Wolfenbuttel | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Associatedpartner |
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Associatedpartner |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
| Sb Science Management UG | Berlin | Germany | Associatedpartner |
| Arjuna Therapeutics S.L. | Ames (A Coruña) | Spain | Associatedpartner |
| Carthera | Paris | France | Associatedpartner |
| Institut Du Cerveau Et De La Moelle Epiniere | Paris | France | Participant |
| Sorbonne Universite | Paris | France | Associatedpartner |
| Laboratoire National De Sante | Dudelange | Luxembourg | Associatedpartner |
| Luxembourg Institute of Health | Strassen | Luxembourg | Participant |
| Universite Du Luxembourg | Esch-Sur-Alzette | Luxembourg | Associatedpartner |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Mimetas BV | Leiden | Netherlands | Participant |
| Oslo Universitetssykehus Hf | Oslo | Norway | Associatedpartner |
| International Brain Tumour Alliance | London | United Kingdom | Associatedpartner |
| The University of Edinburgh | Edinburgh | United Kingdom | Associatedpartner |
| Brigham Inc | Boston | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI